Figure 2. LT-IIa-B₅-induced enhanced uptake of FITC-OVA by BMDC is time- and dose-dependent.

A. Dose-dependence. BMDC incubated for 10 min at 37°C with 0.1, 0.5, 1, 3, 5, or 10 μg/ml of LT-IIa-B₅ were treated with FITC-OVA (0.2 mg/ml) for 10 min, washed with PBS, and stained with an APC-conjugated anti-CD11c mAb. Data are presented as fold change in the MFI of the FITC fluorescence of CD11c-positive, 7-AAD-negative LT-IIa-B₅ treated BMDC to the MFI of the FITC fluorescence of CD11c-positive, 7-AAD-negative untreated BMDC. Error bars denote one standard deviation from the mean obtained from triplicate cultures. B. Time dependence. BMDC incubated at 37°C for 10, 20, or 30 min and 1, 2, 12, or 24 hrs with 5 μg/ml of LT-IIa-B₅ were treated with FITC-OVA (0.2 mg/ml) for 10 min, washed with PBS, and stained with an APC-conjugated anti-CD11c mAb. Data are presented as fold change of MFI of the FITC fluorescence of CD11c-positive, 7-AAD-negative LT-IIa-B₅ treated BMDC to MFI of the FITC fluorescence of CD11c-positive, 7-AAD-negative untreated BMDC. Error bars denote one standard deviation from the mean obtained from triplicate cultures.